Akari Therapeutics Plc (AKTX) shares soared 89.01 percent to $9.72, up $4.58 on Friday, likely continuing momentum from the company's recently announced positive preclinical oncology data ahead of the American Society of Clinical Oncology Annual Meeting 2026.
The stock is currently trading at $9.72, compared with a previous close of $5.14 on the Nasdaq. It opened at $9.91 and traded between $8.78 and $10.91 during the session, with volume reaching 10.88 million shares, far above the average daily volume of 68,240 shares.
Akari Therapeutics Plc said new data showed its lead antibody-drug conjugate candidate, AKTX-101, demonstrated synergistic anti-cancer activity when combined with the KRAS inhibitor adagrasib in KRAS-mutated pancreatic cancer models.
The company said the studies showed enhanced cell killing in KRAS G12C and KRAS G12D mutant cancer cell lines, while comparator TROP2-targeting therapies displayed antagonistic effects in combination testing.
Akari Therapeutics shares have traded between $3.02 and $56.80 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.